Analysis Of Expression Of PAC-1and CD62p In Patients With Acute Leukemia

[Objectives]：PAC1and CD62p are two sensitive markers of the platelet activation.In recent years, research shows that there are significant correlations between theinvasion and metastasis of solid tumor cell and the platelet activation. And acuteleukemia patients with widespread clinical symptoms such as infiltration, hemorrhage arealso associated with the platelet activation. This research attempts to test the expressionsof the markers of platelet activation PAC-1and CD62p in acute leukemia by flowcytometry to provide certain reference for the clinical treatment of acute leukemia.[methods]：1. Data sources: We collect30cases of patients who are all diagnosed with AcuteLeukemia at department of hematology and immunology in Yan’an university affiliatedhospital from May2011to January2013. The age is from the ages of6to76with21AML cases and9ALL cases. ALL cases are determined by bone marrow cytology、cytochemistry and flow cytometry immunophenotype. While ALL patients need to bechecked by using fluorescent hybridization fusion gene BCR/ABL, M3by usingPML-RARα and M2by using AML1-ETO.The number of complete remission group is13cases and the number of continuous complete remission group is10cases. Besides,21cases of healthy patients were collected, whose physical examinations are normal. Thusthe medical history of basic diseases that affect platelet disease is rejected. Before the testof two weeks, the patients did not take medicine that affects the function of plateletactivation. The median age was38.0(16—60), male11cases while female10cases. Wedemand that there is no significant difference in statistics between the healthy controlgroup and patients with leukemia in the general data (age, gender).2. The specific experiments:①We detect the expressions of PAC-1and CD62P in the peripheral blood among the leukemia patients already stage, complete remission (CR),continue to complete remission (CCR) by FCM. And we select the PAC1and CD62P inperipheral blood of the normal people as a contrast.②We use parameter testinginstrument of platelet (PLT), white blood cells (WBC) to test the number changes ofwhite blood cells and platelet between experimental group (peripheral blood of leukemiapatients) and control group (peripheral blood of healthy people).[Results]：1. In30AL patients, there are1patient with thrombosis and19cases withhemorrhage. Thrombosis rate was3%and bleeding rate was63%. After treatment, thereare complete remission (CR) group in21cases. Complete remission rate was70%. Thereare continuous complete remission group (CCR, patients with acute leukemia remissionfor more than3years) in10cases and healthy control group of21cases. There is nosignificant difference in statistics between the healthy control group and patients withnewly diagnosed acute leukemia (age, gender).2. The platelets of newly diagnosed acute leukemia are significantly lower thanthat of the healthy control group, which means there is statistical significance (t=16.59, p<0.001); the number of white blood cells significantly increase (t=9.57, p <0.01),which also has statistical significance. The number of complete remission group aresignificantly lower than that of healthy control group, which means there is statisticalsignificance (t=2.73, p <0.05); there is no significant difference of the white blood cells(p>0.05). As for the continuous complete remission group and the healthy controlgroups, there is no obvious significance in the number of platelets and white bloodcells(t=1.76、1.33，p>0.05).3. The peripheral blood PAC-1,CD62p expression in patients with leukemianewly diagnosed is higher than normal control group, CR, CCR, especially in newlydiagnosed M3group PAC-1, CD62p expression are higher (19.4±1.6%,18.4±1.5%),with statistical significance (p<0.01). The peripheral blood PAC-1, CD62pexpression in complete remission group is higher than the healthy control groups, the CCR groups, with statistically significant differences (p <0.05). The peripheral bloodPAC-1,CD62p expression in continuous complete remission group and health controlgroup has no statistically significant difference(t=1.3、1.08).4. We use the Spearman rank correlation test to test WBC in the peripheral bloodof newly diagnosed acute leukemia and PAC-1. The result shows: the WBC in theperipheral blood of newly diagnosed acute leukemia has positive correlation with PAC1(r=0.73，p<0.01). We use the Spearman rank correlation test to test the relations ofplatelet in the peripheral blood of newly diagnosed acute leukemia and CD62p. Theresult shows: there are positive correlations between WBC in the peripheral blood ofnewly diagnosed acute leukemia and CD62p (r=0.84，p<0.01).5. We use the Spearman rank correlation test to test the relations between platelet inthe peripheral blood of newly diagnosed acute leukemia and PAC-1. The result shows:there is no relations between platelet in the peripheral blood and PAC-1(r=0.22, p>0.05). We use the Spearman rank correlation test to test the relations between platelet inthe peripheral blood of newly diagnosed acute leukemia and CD62p. The result shows:there is no relations between platelet in the peripheral blood and CD62p (r=0.31, p>0.05).[Conclusions]：1. The expression of PAC-1, CD62P in newly diagnosed acute leukemia is higherthan that in healthy control group.2. The expression of PAC1, CD62p in peripheral blood patients of acuteleukemia newly diagnosed is positively correlated with the expression of PAC-1andCD62p. It prompts morbid white may be one of the factors of blood platelet activation.The expression of PAC1, CD62p in peripheral blood of acute leukemia has no relationswith the number of PLT.3. The expression of PAC1, CD62p in peripheral blood of newly diagnosed acuteleukemia patients is higher, especially in newly diagnosed M3group PAC-1, CD62pexpression are much higher.With the illness gradually improving, the expression of PAC 1, CD62p has a downward trend. The expression of PAC1, CD62p in peripheral blood ofCCR groups has returned to normal. Continuous complete remission patients have nosignificant difference with healthy control group. Acute leukemia (especially M3) innewly diagnosed process should pay high attention to thrombosis.